藥碼
HOL02
藥名
Nicardipine 針 10 mg/10 mL/Syr
英文商品名
Holdipine 針 10 mg/10 mL/Syr
中文商品名
欣立定注射液 10毫克/支
螢幕名
Holdipine 針 10 mg/10 mL/Syr
劑型
Inj
規格
Nicardipine HCL 1.0mg/ml
成分
藥理分類
Dihydropyridine C.C Blockers
健保碼
AC58993229
ATC碼
適應症
Hypertension: Management of hypertension (oral and IV); parenteral only for short-term use when oral treatment is not feasible or not desirable.
藥理
Antianginal Agent; Antihypertensive; Calcium Channel Blocker; Calcium Channel Blocker, Dihydropyridine
藥動學
Onset of action:Within minutes (constant infusion)
Peak effect: 50% of the maximum effect is seen by 45 minutes
Duration: <8 hours; upon discontinuation of continuous infusion, a 50% decrease in effect is seen in ~30 minutes with gradual discontinuing antihypertensive effects for ~50 hours.
Distribution: Vd 8.3 L/kg.
Protein binding: >95%.
Metabolism: Hepatic; extensive first-pass effect (saturable); major pathway is via CYP3A4, 2C8, and 2D6.
Half-life elimination: Follow dose-dependent (nonlinear) pharmacokinetics; apparent or calculated half-life is dependent upon serum concentrations. alpha half-life 3 minutes; beta half-life 45 minutes; terminal half-life 14 hours
Excretion: Urine (IV: 49% as metabolites; <1% as unchanged drug); feces (IV: 43%)
Clearance: Decreased in patients with hepatic impairment; may be decreased in patients with renal impairment
Peak effect: 50% of the maximum effect is seen by 45 minutes
Duration: <8 hours; upon discontinuation of continuous infusion, a 50% decrease in effect is seen in ~30 minutes with gradual discontinuing antihypertensive effects for ~50 hours.
Distribution: Vd 8.3 L/kg.
Protein binding: >95%.
Metabolism: Hepatic; extensive first-pass effect (saturable); major pathway is via CYP3A4, 2C8, and 2D6.
Half-life elimination: Follow dose-dependent (nonlinear) pharmacokinetics; apparent or calculated half-life is dependent upon serum concentrations. alpha half-life 3 minutes; beta half-life 45 minutes; terminal half-life 14 hours
Excretion: Urine (IV: 49% as metabolites; <1% as unchanged drug); feces (IV: 43%)
Clearance: Decreased in patients with hepatic impairment; may be decreased in patients with renal impairment
禁忌症
Hypersensitivity to nicardipine or any component of the formulation; advanced aortic stenosis
懷孕分類
C
1. Limited placental transfer following maternal IV administration
2. Risk of adverse maternal events: headache, nausea, tachycardia, acute pulmonary edema (have been reported following use as a tocolytic)
3. Females with preexisting hypertension may continue their medication during pregnancy unless contraindications exist. Nicardipine may be used as an alternative agent for the treatment of acute onset, severe hypertension in pregnant females.
1. Limited placental transfer following maternal IV administration
2. Risk of adverse maternal events: headache, nausea, tachycardia, acute pulmonary edema (have been reported following use as a tocolytic)
3. Females with preexisting hypertension may continue their medication during pregnancy unless contraindications exist. Nicardipine may be used as an alternative agent for the treatment of acute onset, severe hypertension in pregnant females.
哺乳分類
Nicardipine is present in breast milk.
副作用
Flushing, pedal edema, exacerbation of angina pectoris, hypotension, palpitations, headache, dizziness, weakness
劑量和給藥方法
1. Initial 5 mg/hour; may increase by 2.5 mg/hour every 5 minutes (for rapid titration) to every 15 minutes (for gradual titration) up to a maximum of 15 mg/hour
2. Adjust infusion rate as needed to maintain desired response; in rapidly titrated patients, consider reduction to 3 mg/hour after response is achieved
3. Discontinue infusion if unacceptable hypotension or tachycardia occurs.
Note : In general, reduce mean arterial BP ~10% to 20% over the first hour, then 5% to 15% over the next 23 hours, unless there is a compelling indication (eg, acute aortic dissection, severe preeclampsia, eclampsia) for more rapid BP and heart rate control.
1. Initiate 5 mg/hour; titrate by 2.5 mg/hour at 5- to 15-minute intervals to goal target mean arterial pressure (maximum dose: 15 mg/hour).
小兒調整劑量
1. Bolus(optional): Initial 30 mcg/kg, maximum 2 mg/dose
2. Continuous infusion: Initial 0.5 to 1 mcg/kg/minute, titrate dose according to blood pressure; rate of infusion may be increased every 15 to 30 minutes; maximum: 4-5 mcg/kg/minute
2. Continuous infusion: Initial 0.5 to 1 mcg/kg/minute, titrate dose according to blood pressure; rate of infusion may be increased every 15 to 30 minutes; maximum: 4-5 mcg/kg/minute
腎功能調整劑量
There are no specific dosage adjustments provided in the manufacturer's labeling; titrate slowly with careful monitoring; dosage adjustment may be necessary.
肝功能調整劑量
There are no specific dosage adjustments provided in the manufacturer's labeling; titrate slowly with monitoring; dosage adjustment may be necessary.
安定性
仿單: 避光、25℃以下儲存。
注射給藥指引
給藥途徑
IVD (靜脈滴注)
靜脈輸注液
再生溶液：不需再生。稀釋溶液：D5W、NS。
每瓶稀釋液體積
最終濃度：0.1-0.2 mg/mL(仿單)
注射濃度
給藥速率
每12小時需換一次注射部位，無時間相關資料
安定性
仿單: 避光、25℃以下儲存。
注意事項
相容：amiodarone、
bumetanide、
calcium chloride、
calcium gluconate、
cisatracurium、
dexmedetomidine、
diltiazem、
dobutamine、
dopamine、
epinephrine、
esmolol、
fentanyl、
isoproterenol、
labetalol、
lidocaine、
lorazepam、
magnesium sulfate、
mannitol、
midazolam、
milrinone、
nitroglycerin、
norepinephrine、
octreotide、
potassium chloride、
vasopressin
不相容：furosemide、 lansoprazole、pantoloc、sodium bicarbonate
完整資訊請見重症常用藥品靜脈相容性表
不相容：furosemide、 lansoprazole、pantoloc、sodium bicarbonate
完整資訊請見重症常用藥品靜脈相容性表
藥袋資訊
臨床用途
高血壓，本品替代原培爾吉平注射液
主要副作用
低血壓、周邊水腫、心律不整、噁心、嘔吐、頭痛
泡製方法
儲存方式
請置於 15-30℃ 乾燥處儲存
注意事項
其他說明
藥局 a3 | 小庫 A1 | 藥庫 注D12
藥品外觀
顏色
形狀
剝痕
標記1
標記2
其他
健保藥價
98
自費價
130.34
仿單
資料庫
健保給付規定